policymed.com21 時間
Pfizer’s Subsidiary Biohaven Settles for Nearly $60M Over Speaker Programs: Complaint ...
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...
Pharmaceutical Technology on MSN2 日
Pfizer settles Biohaven kickback claims case for $59.7m
Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
BioSpace1 日
Pfizer Gets Breather From Starboard’s Ongoing Assault
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...
BioSpace2 日
Pfizer Settles Biohaven Kickback Suit for Nearly $60M
Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...
Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In ...
Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...
Why Pfizer (PFE) Is One of the Best Cheap Stocks to Buy for 2025?
We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...
Pharmabiz2 日
Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in ...
Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.